Search | Clinical Trials Finder

Conditions: Colorectal Cancer, Pancreatic Cancer
Interventions: KRAS Vaccine with Poly-ICLC adjuvant, Balstilimab, Botensilimab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adverse Childhood Experiences, Endothelial Dysfunction
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Iowa City, Iowa • Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 28
States / cities: Goodyear, Arizona • Anaheim, California • Greenbrae, California + 24 more

Conditions: HIV Infections
Interventions: DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more

Conditions: Ricin Poisoning
Interventions: RVEc; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Fort Deterick, Maryland

Conditions: HIV-1 Infection
Interventions: Vacc-4x; Biological
Lead sponsor: Bionor Immuno AS; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Los Angeles, California • Sacramento, California

Conditions: Healthy
Interventions: Investigational, Placebo; Dietary Supplement · Other
Lead sponsor: Hong Kong Prospect Group Co. Limited; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Healthy Volunteer, HIV Vaccine
Interventions: Ad4-mgag, Ad4-EnvC150, Placebo Comparator, AIDSVAX B/E; Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: GlycosBio Nutritional Supplement + PERT placebo, Standard Nutritional Supplement + PERT; Dietary Supplement
Lead sponsor: GlycosBio, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Biliary Tract Cancers
Interventions: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fibrolamellar Hepatocellular Carcinoma (FLC)
Interventions: DNAJB1-PRKACA peptide vaccine, Nivolumab, Ipilimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 12 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2034
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Smallpox
Interventions: Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 38 Years
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 7
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more

Conditions: Respiratory Syncytial Virus
Interventions: Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 3,317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 62
States / cities: Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more

Conditions: Hair Diseases, Alopecia, Hair Thinning
Interventions: Scalp tattoo, Canfield HairMetrix®, TargetCool, Microneedle-facilitated lidocaine application; Device
Lead sponsor: Recens Medical, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
Interventions: DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab, Ipilimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 12 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: FluMist® live, attenuated, intranasal seasonal influenza vaccine, Fluzone® inactivated influenza virus vaccine; Biological
Lead sponsor: Armed Forces Research Institute of Medical Sciences, Thailand; Government
Eligibility: 18 Years to 49 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 0
States / cities: Not listed

Conditions: Head and Neck Cancer
Interventions: Cetuximab, 5-FU, Hydroxyurea, Twice-daily radiation, Cisplatin, Accelerated fraction radiotherapy with concomitant boost; Drug · Radiation
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/insulin aspart, insulin degludec, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 26
States / cities: Goodyear, Arizona • Phoenix, Arizona • Anaheim, California + 22 more

Conditions: Ricin Poisoning
Interventions: RVEc; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Fort Deterick, Maryland

Conditions: Influenza A Virus, H5N1 Subtype
Interventions: VN, IN, dk/BANG, gf/WA, bhg/QL, AS03 adjuvant, MF59 adjuvant; Biological
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: San Diego, California • Peoria, Illinois • Lenexa, Kansas + 3 more

Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Interventions: Radiation Therapy Boost, Pembrolizumab, Paclitaxel, Carboplatin, Cyclophosphamide, Doxorubicin, Capecitabine; Radiation · Drug
Lead sponsor: Laura M. Spring, MD; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: Medulloblastoma
Interventions: Surgical resection, Ommaya/VPS, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Irradiation, Educational and Media Intervention, SOC, Educational and Media Intervention; Procedure · Drug · Radiation + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 59 Months
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2035
U.S. locations: 10
States / cities: Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more

Conditions: Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia
Interventions: CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab, Fludarabine, Thiotepa; Biological · Drug
Lead sponsor: Paul Szabolcs; Other
Eligibility: 5 Years to 40 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

ACEs, SIRT1, and Premature Vascular Aging in Humans

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

ID Recombinant Ricin Toxin A-Chain Vaccine RVEc™ - 3-Dose Primary Series With Boost

Re-boosting of HIV-1 Infected Subjects With Vacc-4x

A Study to Evaluate the Impact of a Nutritional Product on Cognition in Healthy Teenagers

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

MVA Post-Event: Administration Timing and Boost Study

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus

Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

IM Recombinant Ricin Toxin Vaccine (RVEc) - 3-Dose Primary Series With Boost

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias